Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Protease Inhibitors and Decreased Birth Weight in HIV-Infected Pregnant Women With Impaired Glucose Tolerance

Journal of Perinatology volume 22, pages 370–373 (2002)Cite this article

Abstract

OBJECTIVE: To assess the impact of highly active antiretroviral therapy, including a protease inhibitor (HAART/PI), on maternal glucose tolerance and fetal growth.

STUDY DESIGN: A retrospective chart review of pregnancy outcomes of human immunodeficiency virus–infected pregnant women receiving HAART/PI (n=41) or zidovudine monotherapy (n=23).

RESULTS: Abnormal 1-hour glucose tolerance tests (1hGTT) were observed in 30% of subjects receiving HAART/PI between 24 and 28 weeks' gestation. An elevated 1hGTT was associated with a significantly lower mean birth weight in subjects receiving HAART/PI compared to babies born to mothers with a normal 1hGTT (3.40±0.09 vs 3.00±0.18 kg, p<0.05, ANOVA).

CONCLUSION: HAART/PI therapy is associated with an increased rate of impaired glucose tolerance in pregnancy and impaired fetal growth. This finding merits further investigation.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Connor EM, Sperling RS, Gelber R et al. Reduction of maternal–infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group N Engl J Med 1994; 331: 1173–80

    Article  CAS  Google Scholar 

  2. Flexner C . HIV-protease inhibitors N Engl J Med 1998; 338: 1281–92

    Article  CAS  Google Scholar 

  3. Safrin S, Grunfeld C . Fat distribution and metabolic changes in patients with HIV infection AIDS 1999; 13: 2493–505

    Article  CAS  Google Scholar 

  4. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA . Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor–associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study Lancet 1999; 353: 2093–9

    Article  CAS  Google Scholar 

  5. Murata H, Hruz PW, Mueckler M . The mechanism of insulin resistance caused by HIV protease inhibitor therapy J Biol Chem 2000; 275: 20251–4

    Article  CAS  Google Scholar 

  6. Walli R, Herfort O, Michl GM et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1–infected patients AIDS 1998; 12: F167–73

    Article  CAS  Google Scholar 

  7. Moore TR . Diabetes in pregnancy In: Creasy RK, Resnik R, editors Maternal Fetal Medicine Philadelphia: Saunders 1999

    Google Scholar 

  8. Carpenter MW, Coustan DR . Criteria for screening tests for gestational diabetes Am J Obstet Gynecol 1982; 144: 768–73

    Article  CAS  Google Scholar 

  9. Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M . A United States national reference for fetal growth Obstet Gynecol 1996; 87: 163–8

    Article  CAS  Google Scholar 

  10. Langer O, Brustman L, Anyaegbunam A, Mazze R . The significance of one abnormal glucose tolerance test value on adverse outcome in pregnancy Am J Obstet Gynecol 1987; 157: 758–63

    Article  CAS  Google Scholar 

  11. Pedersen J . Diabetes mellitus and pregnancy: present status of the hyperglycaemia–hyperinsulinism theory and the weight of the newborn baby Postgrad Med J 1971; 66–7 (Supplement)

  12. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ . Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4 Nature 1995; 377: 151–5

    Article  CAS  Google Scholar 

  13. Casey BM, Bawdon RE . Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model Am J Obstet Gynecol 1998; 179: 758–61

    Article  CAS  Google Scholar 

  14. Bawdon RE . The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir Infect Dis Obstet Gynecol 1998; 6: 244–6

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Reproductive Medicine, University of California San Diego, La Jolla, CA, USA

    Ramen Chmait MD & Andrew D Hull MD

  2. Department of Pediatrics, University of California San Diego, La Jolla, CA, USA

    Patricia Franklin MSN & Stephen A Spector MD

Authors
  1. Ramen Chmait MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia Franklin MSN
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephen A Spector MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew D Hull MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chmait, R., Franklin, P., Spector, S. et al. Protease Inhibitors and Decreased Birth Weight in HIV-Infected Pregnant Women With Impaired Glucose Tolerance. J Perinatol 22, 370–373 (2002). https://doi.org/10.1038/sj.jp.7210748

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jp.7210748

This article is cited by

Search

Advanced search

Quick links